Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev 1997; 5: 294-315.
Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type II diabetes mellitus and microalbuminuria: The Steno type II randomised study. Lancet 1999; 353: 617-22.
Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risk of stroke and of coronary heart disease. Br Med Bull 1884; 50: 272-98.
Deedwania PC. Hypertension and diabetes. New therapeutic options. Arch Intern Med 2000; 160: 1585-94.
Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-92.
Hansson L, Zanchetti A, Carruthers SG, et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
Tuomilehto J, Rastenyte D, Birkenhäger WH, et al for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-84.
The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type II diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
Scheen AJ, Weekers L, Lefebvre PJ. Guidelines for the treatment of arterial hypertension in diabetic patients. Int Diabetes Monitor 1998; 10: 1-8.
Guidelines Subcommittee. 1999 World Health Organization - International society of hypertension guidelines for the management of hypertension. J Hypertension 1999; 17: 151-83.
ADA Consensus Statement. Treatment of hypertension in diabetes. Diabetes Care 1996; 19: S107-13.
Bauduceau B, Catellier G, Cordonnier D, et al. Recommandations de l'ALFEDIAM. Hypertension et diabète. Diab Metab 1996; 22: 64-76.
MacLeod MJ, McLay J. Drug treatment of hypertension complicating diabetes mellitus. Drugs 1998; 56: 189-202.
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type II diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipidine as compared with elanapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.
Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randormized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
Hansson L, Lindholm LH, Niskanen L, et al for the Captopril Prevention Project (CAPPP) Study Group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Am J Hypertens 1996; 9: 342-60.
Paquot N, Scheen AJ, Lefèbvre PJ. Pourquoi, quand et comment traiter une hyperlipoprotéinémie chez le patient diabétique? Med Hyg 1990; 48: 2218-24.
Stamler J, et al. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the Multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-44.
Scandinavian Simvastatin Survival Study (4S). Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-20.
Herman WH, Alexander CM, Cook JR, et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care 1999; 22: 1771-8.
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. Circulation 1998; 98: 2513-9.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1948; 339: 1349-57.
Armitrage J. Lipid-lowering trial in diabetes. Eur Heart J 1999; 1 (Suppl. M): M13-M7.
Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated subjects with coronary bean disease and diabetes or impaired fasting glucose: Subgroup analyses in the Scandinavian Simvastatin Survival Study (4S). Arch Int Med 2000 (in press).
Hoogwerf BJ, Waness A, Cressman M, et al. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes. The post-coronary artery bypass graft trial. Diabetes 1999; 48: 1289-94.
Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 160-78.
Frick MH, Haapa K, Heinonen OP, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45.
Rubins BH, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density liproprotein cholesterol. N Engl J Med 1999; 341: 410-8.
Task Force Report. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint task force of european and other societies on coronary prevention. Eur Heart J 1998; 19: 1434-503.
Steiner G. Lipid intervention trial in diabetes. Diabetes Care 2000; 23 (Suppl. 2): B49-B53.
